Cara Therapeutics Inc
CARA
Get informed when a big investor buys or sells
+ FollowMarket Cap$49.91B
Close$
$0.13
97.6% downside
Current Fair Value
97.6% downsideOvervalued by 97.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $49.91 Billion |
|---|---|
| Enterprise Value | $49.89 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.46 |
| Beta | 0.41 |
| Outstanding Shares | 9,381,344,000 |
Return
| Return on Equity | -366.69% |
|---|---|
| Return on Assets | -175.46% |
| Return on Invested Capital | -380.41% |
Valuation & Multiples
| P/E Ratio | -0.34 |
|---|---|
| PEG | 0.13 |
| Price to Sales | -5.32 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 2.92 |
| Enterprise Value to EBIT | 0.23 |
| Enterprise Value to Net Income | -1624 |
| Total Debt to Enterprise | -0.02 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
November 13, 2025
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Cara Therapeutics Inc
12 employees
CEO: Derek Chalmers Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and...